Version July 2025
Diaper dermatitis, candida: Limited data available: Infants ≥2 months and Children <2 years: Cream 2%: Topical: Apply twice daily after a diaper change for 2 weeks; dosing based on an open-label, noncomparative study (n=27; mean age: 5.7 months; range: 2 to 22 months); 88.8% had complete cure; 1 patient had increased erythema but continued treatment (Ref).
Tinea corporis (ringworm): Limited data available: Children ≥2 years and Adolescents: Cream 2%: Topical: Apply 1 to 2 times daily to affected and surrounding area(s) until clinical resolution, typically 2 to 4 weeks (Ref).
Tinea cruris (jock itch): Limited data available: Children ≥2 years and Adolescents: Cream 2%: Topical: Apply 1 to 2 times daily to affected and surrounding area(s) until clinical resolution, typically 2 to 4 weeks (Ref).
Tinea pedis (athlete's foot): Children ≥2 years and Adolescents: Limited data available in ages <12 years: Cream 2%: Topical: Apply twice daily to affected and surrounding area(s) until clinical resolution, typically 4 weeks (Ref).
There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely necessary due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely necessary due to low systemic absorption.
(For additional information see "Sertaconazole: Drug information")
Cutaneous candidiasis (off-label use): Topical: Apply to affected area(s) twice daily for 4 weeks (Ref).
Seborrheic dermatitis (off-label use): Topical: Apply to affected area(s) twice daily for 4 weeks (Ref).
Tinea infection:
Tinea corporis/tinea cruris (off-label use): Topical: Apply to affected and surrounding area(s) 1 to 2 times daily until clinical resolution, typically 1 to 3 weeks (Ref).
Tinea pedis (labeled use)/tinea manuum (off-label use): Topical: Apply to affected and surrounding area(s) twice daily until 1 week after clinical resolution, typically for 4 weeks total (Ref).
Tinea versicolor (pityriasis versicolor) (off-label use): Topical: Apply to affected and surrounding area(s) twice daily for 4 weeks (Ref).
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
There are no dosage adjustments provided in the manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
1% to 10%: Dermatologic: Erythematous condition (4%)
Postmarketing: Dermatologic: Desquamation, hyperpigmentation, pruritus, skin vesicle
There are no contraindications listed in the manufacturer's labeling.
Concerns related to adverse effects:
• Irritation: Discontinue drug if sensitivity or irritation occurs.
Other warnings/precautions:
• Appropriate use: For topical use only; avoid ophthalmologic, oral, or intravaginal use. Re-evaluate use if no response within 2 weeks.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Cream, External, as nitrate:
Ertaczo: 2% (60 g) [contains methylparaben]
No
Cream (Ertaczo External)
2% (per gram): $17.99
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Topical: Cream: For external use only. Apply to affected area(s) and surrounding healthy skin (for tinea, ~1 to 2 cm beyond lesion border (Ref)). Make sure skin is dry before applying; wash hands after application. Avoid use of occlusive dressing. Avoid contact with eyes, mouth, vagina, and other mucous membranes.
Topical: For external use only. Not for oral, ophthalmic, or intravaginal use. Apply to affected and immediately surrounding area(s) as directed. Make sure skin is dry before applying; wash hands after application. Avoid use of occlusive dressing. Avoid contact with eyes, nose, mouth, and other mucous membranes.
Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).
Topical treatment of interdigital tinea pedis in immunocompetent patients (FDA approved in ages ≥12 years and adults); has also been used for diaper dermatitis, tinea corporis, and tinea cruris.
None known.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.
Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program
Progesterone: Antifungal Agents (Vaginal) may decrease therapeutic effects of Progesterone. Risk X: Avoid
Adverse events were not observed in animal reproduction studies following oral administration. Systemic absorption following topical application is limited.
New skin irritation; reassess diagnosis if no clinical improvement after 2 weeks.
Alters fungal cell wall membrane permeability; inhibits the CYP450-dependent synthesis of ergosterol
Absorption: Topical: Minimal; serum concentrations below the limit of quantitation (<2.5 ng/mL)
